Ergomed says that following its recent acquisitions of Dr Oestreich + Partner and Gesellschaft für angewandte Statistik + Datenanalyse mbH in Germany, it has signed its first contract with an existing O+P and GASD customer to provide a significantly broader suite of services from the entire group.
The long-standing customer will be using O+P's proprietary electronic data capture system, OPVERDI.
At the time of the acquisitions, it was noted that O+P and GASD enjoy strong brand awareness in their home markets and that a key rationale for the deals was the potential for cross-selling across offerings available within the broader Ergomed business, providing a "one-stop shop" for clinical trial service needs.
This €1.5 million contract covers six countries and supports Ergomed's broader approach to seek bolt-on acquisitions that further expand and enhance the menu of clinical trial services offered by the Group.
Chief executive Dr. Miroslav Reljanovic said: "I am delighted to announce this contract win with an existing customer of O+P and GASD. The significantly broadened suite of Ergomed services provided to this customer validates the rationale behind our recent acquisitions of these German businesses.
"Offering a comprehensive range of clinical trial solutions will enable us to grow our existing business as well as attract customers from new markets.
"As such, we will continue to seek bolt-on acquisitions that enhance our menu of Services and position Ergomed as a one-stop shop for all our customer's clinical trial service needs."
At 9:22am: (LON:ERGO) Ergomed Plc share price was +0.5p at 120.5p